Form 4: Guardant Health Director Converts RSUs to Stock

Guardant Health Director Manuel Hidalgo Medina converted 232 restricted stock units into common stock on March 17, 2026.

Summary

• Director Manuel Hidalgo Medina acquired 232 shares of Guardant Health, Inc. common stock.
• This acquisition resulted from the vesting and conversion of 232 Restricted Stock Units (RSUs).
• The transaction occurred on March 17, 2026, with a conversion price of $0 per share, typical for RSU vesting.
• Following this transaction, Medina directly owns 1,425 shares of common stock and 6,497 Restricted Stock Units.
• The original RSU award was granted on July 17, 2024, with a vesting schedule of 25% on the one-year anniversary (July 17, 2025) and the remaining 75% vesting monthly over the subsequent three years.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting a standard, pre-scheduled compensation transaction for a director. It neither indicates strong positive nor negative operational performance.

Positives

• Conversion of Restricted Stock Units into common stock indicates a scheduled vesting event, which is a normal part of executive compensation.
• The director's continued ownership of common stock and remaining RSUs aligns their interests with long-term shareholder value.

Negatives

• No direct negatives identified from a routine RSU vesting and conversion.

Risks

• No specific risks are mentioned in this Form 4 filing, as it primarily reports a transaction.

Future Outlook

The vesting schedule for the remaining 6,497 Restricted Stock Units indicates monthly vesting over the three-year period following July 17, 2025, suggesting continued future conversions to common stock.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and conversion, are common in the biotechnology and healthcare diagnostics industry, reflecting standard executive compensation practices. These filings provide transparency into insider holdings but typically do not signal significant strategic shifts unless they involve large, unscheduled open-market purchases or sales.

Comparison to Industry Standards

• This RSU vesting and conversion is a standard compensation event, aligning with practices seen at comparable biotech firms like Illumina or Exact Sciences, where executive compensation often includes equity awards that vest over several years to incentivize long-term performance and retention.
• The $0 conversion price is typical for RSU vesting, as the value is derived from the stock price at the time of vesting, not a purchase price.

Related Party Transactions

• The transaction involves a director of Guardant Health, Inc. acquiring shares from the company as part of an equity compensation plan, which is a common form of related-party transaction in corporate governance.

Stakeholder Impact

• Shareholders: The conversion slightly increases the number of outstanding shares, but this is a planned dilution from equity compensation. It also aligns the director's interests with shareholders.

Next Steps

• Remaining 6,497 Restricted Stock Units will continue to vest monthly over the three-year period following July 17, 2025.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled vesting and conversion of Restricted Stock Units by a director. Such transactions are standard compensation events and typically do not provide new information that would warrant a change in investment recommendation. The director's continued ownership of shares and RSUs aligns their interests with long-term shareholder value, supporting a 'hold' stance based solely on this filing.

Keywords

Guardant Health, GH, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Stock Ownership, Manuel Hidalgo Medina